We and others have successfully used recombinant herpes simplex virus type 1 (HSV-1) vectors to deliver reporter genes to the peripheral and central nervous system. [1] [2] [3] As more efficient vectors are being designed, the potential of gene delivery for the treatment of disease is becoming a real possibility. However, the expression of more than one gene may be required for such treatments to be of maximum benefit, or alternatively, the expression of a reporter gene in addition to the functional transgene could aid experimental assessment of gene transfer efficiencies and optimisation of the gene transfer process.
The current strategies for expressing two transgenes in the same gene delivery vector can be either to use two promoters, thus expressing each gene separately, or to insert an internal ribosome entry site (IRES), from encephalomyocarditis virus (ECMV) or another picornavirus, between the two transgenes to enable transcription of both coding regions from a single promoter and thus translation of both genes from a single mRNA. 4 The potential problem with the use of two promoters in a viral vector is that the promoter driving reporter gene activity may not mimic the activity of the promoter driving the functional transgene. If an identical promoter is used to drive the expression of each transgene separately, the two promoters may be susceptible to homologous recombination resulting in an unstable vector virus or competition for endogenous factors may reduce gene expression levels. Also, as recombinant virus plaques are often selected by reporter gene activity, false positives may be selected during plaque purification.
The EMCV IRES enables cap-independent translation of mRNA. In a defective HSV-1 amplicon vector it was demonstrated that insertion of the EMCV IRES between the glucose transporter gene (upstream) and the reporter gene lacZ, encoding ␤-galactosidase, (downstream) successfully enabled translation of both genes from a single mRNA species when transcribed under the control of the HSV-1 ICP4 promoter. 5, 6 It was also reported that gene expression by cap-independent translation by way of the IRES was not as efficient as cap-dependent translation. The EMCV IRES has also been used successfully to generate bicistronic transcripts in adenoviral, adeno-associated viral and retroviral gene delivery strategies. [7] [8] [9] The use of recombinant HSV-1 vectors for transgene delivery to the central nervous system has several potential advantages over other viral strategies. Recombinant HSV-1 vectors that have had one or more essential genes deleted can enter a latent state in neurons, transcribing only the latency-associated transcript (LAT) and thus they provide the possibility of long-term gene transfer to the nervous system. HSV also has a large genome (152 kb), and thus large sequences can be stably inserted into the locus of choice, which is not always the case with other vectors where packaging capabilities are more limited. Unlike HSV amplicon vectors which are grown with a helper virus, often resulting in unreliable ratios of amplicon and helper virus in such stocks, the growth of disabled HSV vectors is less problematical as long as a cell line effectively complementing the deletions in the virus is used.
We aimed to use a similar approach, using an ECMV 1, 12 IRES in the context of a recombinant disabled HSV-1 vector, to that which has previously been used in an amplicon vector and reported previously. 5, 6 We therefore inserted an EMCV IRES between the green fluorescent protein (GFP) and lacZ genes driven by a CMV promoter in a virus deleted for the essential gene ICP27, and compared the expression of the two reporter genes with similar recombinant viruses in which only a single reporter gene is inserted.
Figure 1 Schematic representation of the 17+pR19-based HSV-1 vectors. The long repeat region of the HSV-1 genome is shown (not to scale). In (a) the loci of the LAT promoters, the coding regions of the major and minor LATs and ICP0 (IE1) are shown. The structure of the expression cassettes inserted into the LAT region is shown in (b
The IRES has previously been used in a recombinant HSV-1 backbone, downstream of the LAT promoter, 3 but only to express a single gene. Here, lacZ was inserted in place of the 2 kb LAT downstream of the LAT promoter. There was a 1.5 kb sequence between the LAT promoter and the lacZ gene which contains 10 AUG codons thereby preventing ribosomal access to the lacZ start codon. Insertion of the IRES directly upstream to the lacZ gene allowed cap-independent translation of the reporter gene irrespective of the start site of transcription and stable expression of the lacZ gene during latency was achieved.
In order to extend these data to allow the expression of pairs of genes, we report in vitro that not only are both genes effectively expressed, albeit at lower levels than with either virus expressing the genes individually, but that both genes are also effectively expressed in the rat brain in vivo.
We have previously shown that recombinant HSV-1 vectors disabled by deletion of the infected cell protein 27 (ICP27) essential gene successfully infect and express transgenes in both cardiac and neuronal cells in vivo. 10, 11 Therefore, the vectors used for this study were also deleted for ICP27. Transgene expression was driven by the human cytomegalovirus immediate-early (CMV IE) promoter and the promoter/transgene cassette was inserted by homologous recombination into the 2 kb LAT sequence in the HSV-1 genome (strain 17+). We have found that a CMV promoter placed at this position in viruses which are attenuated but still replication competent allows efficient gene expression during latency in dorsal root ganglia (DRGs) after footpad inoculation of mice (unpublished results), but in the brain or in DRGs using a virus deleted for only ICP27, long-term expression is only seen in a few cells. This is probably due to remaining toxicity of ICP27-deleted viruses in the
Figure 2 Reporter gene expression in B130/2 cells infected with the 17+pR19 recombinant HSV-1 vectors. Photomicrographs at original ×100 magnification of virus plaques in ICP27-complementing B130/2 cells infected with (a) and (b) 17+pR19 IRES, (c) 17+pR19 lacZ and (d) 17+pR19 GFP 48 h after infection with the respective viruses. GFPexpressing plaques (b, d) were visualised by fluorescence microscopy using fluorescein optics. ␤-Galactosidase-expressing plaques (a, c) were visualised under a light microscope after fixing for 10 min in 0.05% glutaraldehyde in phosphate-buffered saline, and incubation for 2 h with the chromogenic substrate X-gal (4-chloro,5-bromo,3-indolyl-␤-galactosidase). 6 In (e) levels of lacZ expression were quantified after infecting BHK and ND7 cells in six-well plates at a multiplicity of infection of 10 using a commercially available luminometry assay (GalactoLight, Tropix, Bedford, MA, USA) according to the manufacturer's instructions. Results are shown 24 h after infection as activity (luminescence intensity) per 1000 cells assayed above that of non-infected control cells.
brain, and due to a requirement for limited replication for efficient delivery to DRGs after footpad inoculation. The ICP27-deleted viruses reported here are thus only appropriate for testing the activity of promoters in the short term in the brain, and thus the effectiveness of the ECMV IRES at allowing the expression of pairs of genes in the context of the HSV genome was only tested at such times in the experiments reported here.
Three recombinant viruses were constructed: 17+pR19 lacZ, 17+pR19 GFP and 17+pR19 IRES, containing either GFP, lacZ, or GFP and lacZ separated by the IRES, respectively. These are shown in Figure 1 . Each virus was plaque purified following homologous recombination of the respective plasmids into ICP27-deleted virus DNA. 11 The photomicrographs in Figure 2 clearly demonstrate that in B130/2 cells infected with the 17+pR19 IRES virus (Figure 2a and b) where the deletion of ICP27 is complemented, both reporter genes are expressed to a high level. However, it is also clear that the expression of both the transgene upstream and downstream of the EMCV IRES is decreased in comparison to B130/2 cells infected with the single transgene-expressing 17+pR19 lacZ and 17+pR19 GFP viruses (Figure 2c and d) . When the level of lacZ activity (ie the gene downstream of the IRES sequence in the 17+pR19 IRES virus) was directly compared between 17+pR19 IRES and 17+pR19 lacZ when each was used to infect noncomplementing BHK and ND7 cells (a cell line derived from sensory neurons) in which the viruses cannot grow, this result was confirmed showing a 10-to 15-fold reduction in activity when the lacZ gene was preceded by the IRES sequence in each case (Figure 2e ). The GFP fluorescence intensity was also visibly reduced. Thus, while the expression of pairs of genes can be facilitated by the use of an ECMV IRES in a disabled HSV vector, gene expression levels are reduced compared with the situation where each gene is expressed separately.
It has previously been noted that cap-independent translation is not as effective as cap-dependent translation. 5 This would explain the decreased levels of expression of lacZ in cells infected with 17+pR19 IRES compared with similar cells infected with 17+pR19 lacZ, but does not explain why the level of expression of the GFP gene is also reduced compared with cells infected with 17+pR19 GFP. One possibility may be that the addition of an IRES or the lacZ gene may introduce sequences that destabilise the mRNA in some way or otherwise affects RNA processing such that translational efficiency is reduced.
Following the in vitro experiments, gene expression in vivo using 17+pR19 IRES was tested in the rat brain. Here, 2 × 10 6 p.f.u. of 17+pR19 IRES in 4 l of DMEM was inoculated by stereotactical injection into the rat striatum under general anaesthetic, uniformly over a period of 10 min. After 2 days brain sections were visualised under UV light for GFP expression (fluorescein optics), or fixed and stained with the chromogenic substrate X-gal for lacZ expression. Figure 3 shows the same brain section before staining with X-gal, showing GFP expression, and then subsequently following staining, showing lacZ expression. During the staining process co-expression of GFP and lacZ could easily be visualised in the same cells, clearly demonstrating that the ECMV IRES is functional in the nervous system in vivo, and that both genes are effectively co-expressed.
The work presented here therefore shows that the use of an IRES sequence is a practical alternative to the use of separate promoters in strategies requiring the expression of two transgenes in the context of a recombinant HSV-1 vector. The ECMV IRES allows effective expression of pairs of genes both in vitro and in the rat central nervous system in vivo. The principle potential advantage here is that if a reporter gene is inserted downstream of the EMCV IRES, and expression is detected, then any upstream gene must also have been transcribed and is thus likely to have been expressed. This may be useful, for example, when quantifying the effects of a transgene in reducing cell death in conditions of cell stress. Here, the presence of a reporter gene can confirm cell viability over a time-course, the expression of the downstream reporter also mimicking the expression of the upstream transgene which is under test. Bipromoter vector strategies may not necessarily effectively demonstrate these points as the expression of both genes is not necessarily linked.
